Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Lacey E, Dobrolecki"'
Autor:
Emel Alkim, Heidi Dowst, Julie DiCarlo, Lacey E. Dobrolecki, Anadulce Hernández-Herrera, David A. Hormuth, Yuxing Liao, Apollo McOwiti, Robia Pautler, Mothaffar Rimawi, Ashley Roark, Ramakrishnan Rajaram Srinivasan, Jack Virostko, Bing Zhang, Fei Zheng, Daniel L. Rubin, Thomas E. Yankeelov, Michael T. Lewis
Publikováno v:
Tomography, Vol 9, Iss 2, Pp 810-828 (2023)
Co-clinical trials are the concurrent or sequential evaluation of therapeutics in both patients clinically and patient-derived xenografts (PDX) pre-clinically, in a manner designed to match the pharmacokinetics and pharmacodynamics of the agent(s) us
Externí odkaz:
https://doaj.org/article/e0d87f8b7a8e4f92951123a867d724ef
Autor:
Donna M. Peehl, Cristian T. Badea, Thomas L. Chenevert, Heike E. Daldrup-Link, Li Ding, Lacey E. Dobrolecki, A. McGarry Houghton, Paul E. Kinahan, John Kurhanewicz, Michael T. Lewis, Shunqiang Li, Gary D. Luker, Cynthia X. Ma, H. Charles Manning, Yvonne M. Mowery, Peter J. O'Dwyer, Robia G. Pautler, Mark A. Rosen, Raheleh Roudi, Brian D. Ross, Kooresh I. Shoghi, Renuka Sriram, Moshe Talpaz, Richard L. Wahl, Rong Zhou
Publikováno v:
Tomography, Vol 9, Iss 2, Pp 657-680 (2023)
The availability of high-fidelity animal models for oncology research has grown enormously in recent years, enabling preclinical studies relevant to prevention, diagnosis, and treatment of cancer to be undertaken. This has led to increased opportunit
Externí odkaz:
https://doaj.org/article/315dd791b13b4c40966ef7abc8d61d4c
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor:
Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz:
https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be
Autor:
Oscar D Murillo, Varduhi Petrosyan, Emily L LaPlante, Lacey E Dobrolecki, Michael T Lewis, Aleksandar Milosavljevic
Publikováno v:
PLoS Computational Biology, Vol 19, Iss 8, p e1011365 (2023)
Proper characterization of cancer cell states within the tumor microenvironment is a key to accurately identifying matching experimental models and the development of precision therapies. To reconstruct this information from bulk RNA-seq profiles, we
Externí odkaz:
https://doaj.org/article/006f994a827e452db20048595c03626a
Autor:
Varduhi Petrosyan, Lacey E. Dobrolecki, Emily L. LaPlante, Ramakrishnan Rajaram Srinivasan, Matthew H. Bailey, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Aleksandar Milosavljevic
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-5 (2022)
Abstract TNBC is a heterogeneous subtype of breast cancer, and only a subset of TNBC can be established as PDXs. Here, we show that there is an engraftment bias toward TNBC with low levels of immune cell infiltration. Additionally, TNBC that failed t
Externí odkaz:
https://doaj.org/article/df1189d5619f478396baf68cd383f8f1
Autor:
Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian Thistlethwaite, Alaina N. Lewis, Christina Sallas, Ramakrishnan R. Srinivasan, Jonathan T. Lei, Vladimir Kovacevic, Predrag Obradovic, Matthew J. Ellis, C. Kent Osborne, Mothaffar F. Rimawi, Anne Pavlick, Maryam Nemati Shafaee, Heidi Dowst, Antrix Jain, Alexander B. Saltzman, Anna Malovannaya, Elisabetta Marangoni, Alana L. Welm, Bryan E. Welm, Shunqiang Li, Gerburg M. Wulf, Olmo Sonzogni, Chen Huang, Suhas Vasaikar, Susan G. Hilsenbeck, Bing Zhang, Aleksandar Milosavljevic, Michael T. Lewis
Publikováno v:
iScience, Vol 26, Iss 1, Pp 105799- (2023)
Summary: Although systemic chemotherapy remains the standard of care for TNBC, even combination chemotherapy is often ineffective. The identification of biomarkers for differential chemotherapy response would allow for the selection of responsive pat
Externí odkaz:
https://doaj.org/article/2b0f86504c374089a6c4e5c09a09e1cb
Autor:
Arturo B. Ramirez, Raksha Bhat, Debashish Sahay, Carmine De Angelis, Hariprasad Thangavel, Sina Hedayatpour, Lacey E. Dobrolecki, Agostina Nardone, Mario Giuliano, Chandandeep Nagi, Mothaffar Rimawi, C. Kent Osborne, Michael T. Lewis, Jackie L. Stilwell, Eric P. Kaldjian, Rachel Schiff, Meghana V. Trivedi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Breast cancer patient-derived xenograft (BC-PDX) models represent a continuous and reproducible source of circulating tumor cells (CTCs) for studying their role in tumor biology and metastasis. We have previously shown the utility
Externí odkaz:
https://doaj.org/article/cda25575e8d7448795627f419d53ae17
Autor:
Mariah J. Berner, Lily Baek, Junegoo Lee, Philip L. Lorenzi, Mei Leng, Alexander B. Saltzman, Anna Malovannaya, Lacey E. Dobrolecki, Christina Sallas, Michael T. Lewis, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
BACKGROUND: Nearly 50% of patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) retain residual tumors resulting in high rates of metastatic relapse and poor overall survival. Residual tumors surviving NACT (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c47b669b4dc7c0b0dc2d0b018d0049a5
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-10
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-10
Autor:
Jonathan T. Lei, Chen Huang, Ramakrishnan R. Srinivasan, Suhas Vasaikar, Lacey E. Dobrolecki, Alaina N. Lewis, Na Zhao, Jin Cao, Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar Rimawi, Matthew J. Ellis, Varduhi Petrosyan, Alexander B. Saltzman, Anna Malovannaya, John D. Landua, Bo Wen, Antrix Jain, Gerburg M. Wulf, Shunqiang Li, Daniel C. Kraushaar, Tao Wang, Xi Chen, Gloria V. Echeverria, Meenakshi Anurag, Bing Zhang, Michael T. Lewis
Publikováno v:
Cancer Research. 83:P2-23
Background: Triple-negative breast cancer (TNBC) patients frequently receive combination chemotherapy treatment, but a direct comparison of response to carboplatin, docetaxel, and their combination in 50 TNBC patient-derived xenografts (PDXs) showed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5115ca00f0415091ae7a90683abd9716
https://doi.org/10.1158/1538-7445.sabcs22-p2-23-01
https://doi.org/10.1158/1538-7445.sabcs22-p2-23-01
Autor:
Katherine E. Pendleton, Mokryun L. Baek, Junegoo Lee, Lin Tan, Hannah L. Johnson, Lacey E. Dobrolecki, James P. Barrish, Michael T. Lewis, Philip L. Lorenzi, Fabio Stossi, Gloria V. Echeverria
Publikováno v:
Cancer Research. 83:P6-11
Background: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype for which limited targeted therapies are available. Therefore, conventional chemotherapy remains the backbone of standard neoadjuvant treatment (NACT) for TNBC pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f1fa69cc4206aa91aa6feea094f5ab
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15
https://doi.org/10.1158/1538-7445.sabcs22-p6-11-15